0001209191-15-061523.txt : 20150717
0001209191-15-061523.hdr.sgml : 20150717
20150717163632
ACCESSION NUMBER: 0001209191-15-061523
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150715
FILED AS OF DATE: 20150717
DATE AS OF CHANGE: 20150717
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Horizon Pharma plc
CENTRAL INDEX KEY: 0001492426
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 272179987
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CONNAUGHT HOUSE, 1ST FLOOR
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
BUSINESS PHONE: 011-353-1-772-2100
MAIL ADDRESS:
STREET 1: CONNAUGHT HOUSE, 1ST FLOOR
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
FORMER COMPANY:
FORMER CONFORMED NAME: HORIZON PHARMA, INC.
DATE OF NAME CHANGE: 20100520
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SHERMAN JEFFREY W
CENTRAL INDEX KEY: 0001230482
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35238
FILM NUMBER: 15994120
MAIL ADDRESS:
STREET 1: C/O IDM PHARMA, INC.
STREET 2: 9 PARKER, SUITE 100
CITY: IRVINE
STATE: CA
ZIP: 92618
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-07-15
0
0001492426
Horizon Pharma plc
HZNP
0001230482
SHERMAN JEFFREY W
C/O HORIZON PHARMA PLC
CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD
DUBLIN
L2
4
IRELAND
0
1
0
0
EVP and Chief Medical Officer
Ordinary Shares
2015-07-15
4
M
0
24437
2.40
A
137319
D
Ordinary Shares
2015-07-15
4
S
0
24437
35.55
D
112882
D
Ordinary Shares
2015-07-15
4
M
0
2450
4.96
A
115332
D
Ordinary Shares
2015-07-15
4
S
0
2450
35.55
D
112882
D
Stock Option (Right to Buy)
2.40
2015-07-15
4
M
0
24437
0.00
D
2023-01-01
Ordinary Shares
24437
26563
D
Stock Option (Right to Buy)
4.96
2015-07-15
4
M
0
2450
0.00
D
2021-12-07
Ordinary Shares
2450
51171
D
Includes 10,549 ordinary shares of the Issuer acquired by the reporting person on June 1, 2015 pursuant to an employee stock purchase program.
The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on May 13, 2015.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.09 to $35.92 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock option vests in 48 equal monthly installments following the date of grant.
/s/ Paul W. Hoelscher, Attorney-in-Fact
2015-07-17